NodosinCAS# 10391-09-0 |
- Epinodosin
Catalog No.:BCN3282
CAS No.:20086-60-6
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 10391-09-0 | SDF | Download SDF |
| PubChem ID | 430943 | Appearance | Powder |
| Formula | C20H26O6 | M.Wt | 362.4 |
| Type of Compound | Diterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| SMILES | CC1(CCC2C3(C1C(OC3)O)C4C(CC5CC4(C(=O)C5=C)C(=O)O2)O)C | ||
| Standard InChIKey | WZYJEEIAFBHYJS-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C20H26O6/c1-9-10-6-11(21)13-19(7-10,15(9)22)17(24)26-12-4-5-18(2,3)14-16(23)25-8-20(12,13)14/h10-14,16,21,23H,1,4-8H2,2-3H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Nodosin has anti-inflammatory function of Nodosin via inhibition of IL-2. 2. Nodosin perfusion provides a potential protective effect through inducing HO-1 expression to attenuate ischemia/reperfusion injury in liver transplantation. |
| Targets | IL Receptor | HO-1 |
Nodosin Dilution Calculator
Nodosin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.7594 mL | 13.7969 mL | 27.5938 mL | 55.1876 mL | 68.9845 mL |
| 5 mM | 0.5519 mL | 2.7594 mL | 5.5188 mL | 11.0375 mL | 13.7969 mL |
| 10 mM | 0.2759 mL | 1.3797 mL | 2.7594 mL | 5.5188 mL | 6.8985 mL |
| 50 mM | 0.0552 mL | 0.2759 mL | 0.5519 mL | 1.1038 mL | 1.3797 mL |
| 100 mM | 0.0276 mL | 0.138 mL | 0.2759 mL | 0.5519 mL | 0.6898 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- (-)-Isodocarpin
Catalog No.:BCN3280
CAS No.:10391-08-9
- Maxacalcitol
Catalog No.:BCC1730
CAS No.:103909-75-7
- 17β-Hydroxy-17-methylandrosta-4,9(11)-dien-3-one
Catalog No.:BCC8444
CAS No.:1039-17-4
- Mannioside A
Catalog No.:BCN5853
CAS No.:1038922-95-0
- MK-4827 Racemate
Catalog No.:BCC5179
CAS No.:1038915-75-1
- MK-4827 tosylate
Catalog No.:BCC4174
CAS No.:1038915-73-9
- MK-4827 hydrochloride
Catalog No.:BCC4173
CAS No.:1038915-64-8
- MK-4827
Catalog No.:BCC1761
CAS No.:1038915-60-4
- Lacidipine
Catalog No.:BCC4403
CAS No.:103890-78-4
- Procyanidin A1
Catalog No.:BCN6809
CAS No.:103883-03-0
- Cycloart-25-ene-3,24-diol
Catalog No.:BCN5852
CAS No.:10388-48-4
- Lazabemide hydrochloride
Catalog No.:BCC7371
CAS No.:103878-83-7
- Lupeol caffeate
Catalog No.:BCN5855
CAS No.:103917-26-6
- Oleanolic acid 3-O-beta-D-glucosyl-(1->3)-alpha-L-rhamnosyl(1->2)-alpha-L-arabinoside
Catalog No.:BCN8132
CAS No.:103956-33-8
- 15-Nor-14-oxolabda-8(17),12-dien-18-oic acid
Catalog No.:BCN1637
CAS No.:1039673-32-9
- Esculentic acid
Catalog No.:BCN5856
CAS No.:103974-74-9
- Ceftiofur hydrochloride
Catalog No.:BCC8911
CAS No.:103980-44-5
- 13-Hydroxygermacrone
Catalog No.:BCN3556
CAS No.:103994-29-2
- 4'-Hydroxypiptocarphin A
Catalog No.:BCN7113
CAS No.:103994-39-4
- 4-Methoxyphenylacetic acid
Catalog No.:BCN8467
CAS No.:104-01-8
- Anethole
Catalog No.:BCN5373
CAS No.:104-46-1
- Cinnamyl alcohol
Catalog No.:BCN4967
CAS No.:104-54-1
- Cinnamaldehyde
Catalog No.:BCN6241
CAS No.:104-55-2
- Tussilagone
Catalog No.:BCN2770
CAS No.:104012-37-5
Preconditioning donor liver with Nodosin perfusion lessens rat ischemia reperfusion injury via heme oxygenase-1 upregulation.[Pubmed:22098251]
J Gastroenterol Hepatol. 2012 Apr;27(4):832-40.
BACKGROUND AND AIM: Ischemia reperfusion injury (IRI) remains a major cause of graft injury, dysfunction and even failure post-transplantation. Heme oxygenase 1 (HO-1) has been found to be an attractive target for anti-inflammatory therapies and a potential candidate responsible for cell injury. The objective of this study was to investigate whether preconditioning the donor liver with Nodosin perfusion upregulates HO-1 and then lessens IRI in rat models. METHODS: Wistar rats were divided into four groups: experimental group, control group, positive control group and negative control group in which the donor liver was preconditioned with Nodosin, lactated ringer's solution, cobalt protoporphyrin and zinc protoporphyrin perfusion, respectively. We measured HO-1 expression and enzyme activity in rat livers of each group ex vivo at 0, 1 and 2 h after perfusion. At 1 h after perfusion, donor livers of Wistar rats were transplanted into Sprague-Dawley rats orthotopically. Serum transaminase levels, degree of cell apoptosis and Suzuki's score were used to assess ischemia/reperfusion injury in recipients at 24 h after transplantation. RESULTS: Ex vivo, donor liver preconditioning with Nodosin perfusion induced HO-1 expression and enzyme activity significantly, compared with the control group (P < 0.05). In vivo, serum transaminase levels, cell apoptosis degree and Suzuki's score of representative recipients in the Nodosin group were lower than that in the control group (P < 0.05). Preconditioning with Nodosin perfusion induced HO-1 protein mainly in Kupffer cells. CONCLUSIONS: This study suggests that preconditioning with Nodosin perfusion provides a potential protective effect through inducing HO-1 expression to attenuate ischemia/reperfusion injury in liver transplantation.
Anti-inflammatory function of Nodosin via inhibition of IL-2.[Pubmed:20128050]
Am J Chin Med. 2010;38(1):127-42.
In order to explore the anti-inflammatory effects of Nodosin from Isodon serra, a traditional Chinese herb medicine, mouse T lymphocytes were incubated with Nodosin. In the current study, Nodosin suppressed the overproduction of the T lymphocytes; moreover, cell mitosis cycle was modulated by interfering with DNA replication in G1 stages via inhibition of IL-2 cytokine secretion at the mRNA level by Nodosin. Interestingly, Xylene-induced mouse tumescence model results suggested Nodosin depressed the murine ear-swelling extent and the level of IL-2 in the blood serum. Finally, Nodosin possessed significant anti-inflammatory effects and is a potential candidate for further clinical trial.
